TRIL · Trillium Therapeutics Inc

-

Please sign in to comment on TRIL

1 Comment

Admin

4 years, 10 months ago

Trillium Therapeutics Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.

From a valuation standpoint, the stock is 363.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6202.2.

Trillium Therapeutics Inc's total revenue sank by 73.4% to $33K since the same quarter in the previous year.

Its net income has increased by 373.1% to $114M since the same quarter in the previous year.

Finally, its free cash flow fell by 9.1% to $-5M since the same quarter in the previous year.

Based on the above factors, Trillium Therapeutics Inc gets an overall score of 1/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	CA89620X5064
Sector	Healthcare
Industry	Biotechnology

Beta	nan
Target Price	23.41
Dividend Yield	0.0%
Market Cap	2B
PE Ratio	None

ABOUT

Trillium Therapeutics Inc

Under normal circumstances, the fund will invest at least 80% of its net assets, plus borrowings for investment purposes, in equity securities of Trillion Companies and/or financial instruments (such as swaps) that provide indirect exposure to Trillion Companies. The index tracks the performance of U.S. exchange-listed companies with market capitalizations of $1 trillion or greater ("Trillion Companies"). The fund is non-diversified.

TRIL · Trillium Therapeutics Inc

-

Trillium Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Trillium Therapeutics Inc using a moving average strategy